We examined the effect of the A 3 adenosine receptor (AR) agonist IB-MECA on infarct size in an open-chest anesthetized dog model of myocardial ischemia/reperfusion injury. Dogs were subjected to 60 minutes of left anterior descending (LAD) coronary artery occlusion and 3 hours of reperfusion. Infarct size and regional myocardial blood flow were assessed by macrohistochemical staining with triphenyltetrazolium chloride and radioactive microspheres, respectively. Four experimental groups were studied: vehicle control (50% DMSO in normal saline), IB-MECA (100 µg/kg i.v. bolus) given 10 minutes before the coronary occlusion, IB-MECA (100 µg/kg i.v. bolus) given 5 minutes before initiation of reperfusion, and IB-MECA (100 µg/kg i.v. bolus) given 10 minutes before coronary occlusion in dogs pretreated 15 minutes earlier with the ATP-dependent potassium (K ATP ) channel antagonist glibenclamide (0.3 mg/kg i.v. bolus). Administration of IB-MECA had no effect on any hemodynamic parameter measured including heart rate, left ventricular dP/dt, aortic pressure, LAD coronary blood flow, or coronary collateral blood flow. Nevertheless, pretreatment with IB-MECA before coronary occlusion produced a marked reduction in infarct size (~40% reduction) compared to the control group (13.0 ± 3.2% versus 25.2 ± 3.7% of the area-at-risk, respectively). This effect of IB-MECA was blocked completely in dogs pretreated with glibenclamide (0.3 mg/kg). An equivalent reduction in infarct size was observed when IB-MECA was administered immediately before reperfusion (13.1 ± 3.9%). These results are the first to demonstrate efficacy of an A 3 AR agonist in a large animal model of myocardial infarction by mechanisms that are unrelated to changes in hemodynamic parameters and coronary blood flow. These data also H-01001-2002-R2 3 demonstrate in an in vivo model that IB-MECA is effective as a cardioprotective agent when administered at the time of reperfusion.
Introduction
The physiological actions of adenosine are mediated by four adenosine receptor (AR) subtypes designated A 1 , A 2A , A 2B , and A 3 (1, 12) . In the cardiovascular system, A 1 ARs are classically known to be the receptor subtype expressed in cardiac myocytes responsible for the bradycardic and anti-adrenergic actions of adenosine, whereas A 2A ARs are best known to be expressed in vascular smooth muscle cells where they produce vasodilation. (1) The A 3 AR is the most recently identified AR subtype (24) .
Although A 3 AR message is expressed in many different tissues including the heart, its physiological functions remain unknown (24) . (3, 6, 41) . The full-length canine A 1 and A 3 AR were subcloned into the mammalian expression vector pCDNA3.1, transfected into HEK 293 cells using lipofectamine, and then selected with 2 mg/ml of G418. Following antibiotic selection, the cells were maintained in DMEM cell culture media containing 10% fetal bovine serum with 0.6 mg/ml of G418. Cell membranes were prepared and then incubated with 125 I-AB-MECA in the presence of inhibitors (3, 6, 41) . The binding data were analyzed, as described previously (3, 6) .
Anesthetized Dog Model. A standard barbital-anesthetized dog model was employed, as described previously in detail (2, 4) . All dogs were subjected to 60 minutes of LAD occlusion and 3 hours of reperfusion. Dogs were randomly a ssigned to one of four experimental groups: vehicle (1 ml solution of 50%DMSO in normal saline) given 10 minutes before coronary occlusion, IB-MECA (100 µgkg i.v. bolus) given 10 minutes before coronary occlusion, IB-MECA (100 µg/kg i.v.bolus) given 5 minutes before reperfusion, and IB-MECA (100 µg/kg i.v. bolus) given 10 minutes before coronary occlusion in dogs pretreated 15 minutes earlier with the ATP-dependent potassium (K ATP ) channel antagonist glibenclamide (0.3 mg/kg i.v. bolus).
Glibenclamide was administered at a dose that we have shown previously to have no effect on infarct size in our dog model. (16) In all of the groups, hemodynamic H-01001-2002-R2 6 measurements and arterial blood gases were obtained before occlusion, at 30 minutes of the 60-minute occlusion period, and every hour after reperfusion. Regional myocardial blood flow was measured at 30 minutes during the 60-minute occlusion period and at the end of the experiment. Throughout the ischemia/reperfusion experiments, heart rate was maintained at 150 beats/minute by left atrial pacing.
After 3 hours of reperfusion, the anatomic area-at-risk (AAR) and the non-ischemic area were demarcated by staining with Evan's blue dye (2, 4) . The hearts were electrically fibrillated, removed, and prepared for infarct size determination (using triphenyltetrazolium choride) and regional myocardial blood flow measurements (2, 4).
Infarcted and non-infarcted tissues within the area-at-risk were separated and determined gravimetrically. Regional myocardial blood flow was measured by the radioactive microsphere technique (2, 4) . Dogs were excluded from the study if subendocardial collateral blood flow was greater than 0.15 ml/min/gm or if more than three consecutive attempts were required to convert ventricular fibrillation with lowenergy direct current pulses. 
Results
Pharmacology of IB-MECA. Based on radioligand binding analysis with recombinant canine receptors, IB-MECA was found to be ~50-fold selective at binding to the high affinity form of the A 3 AR versus the high affinity form of the A 1 AR (Figure 1 ). The dissociation constants were calculated to be 0.67 ± 0.09 nM and 33.8 ± 2.97 nM for the A 3 and A 1 ARs, respectively.
In preliminary studies, we examined the actions of IB-MECA on systemic hemodynamic parameters including heart rate, mean arterial blood pressure, left ventricular (LV) pressure, LV dP/dt, and LAD coronary artery blood flow in un-paced dogs. Bolus administration of IB-MECA (100 µg/kg) had no effect on any systemic hemodynamic parameter measured for at least 30 minutes (Figure 2 ). In contrast, an equivalent dose of the A 1 AR agonist CCPA caused short-lived decreases in heart rate, LV systolic pressure, LV dP/dt, and mean arterial blood pressure. CCPA also produced a marked increase in coronary blood flow. Ischemia/reperfusion data. A total of 33 dogs were initially included in the infarction study. One dog was excluded from the control group because of intractable ventricular fibrillation and one dog was excluded from the group given IB-MECA at reperfusion because of high collateral blood flow. Thus, a total of 31 dogs were included in the data analysis.
Hemodynamic and regional myocardial blood flow data are shown in Tables 1 and 2 .
There were no significant differences within or between groups throughout the experiment with regard to heart rate, mean arterial blood pressure, LV dP/dt, the rate-
8 pressure product or regional myocardial blood flow in either the non-ischemic or ischemic regions, with the exception of a significant increase in mean arterial blood pressure at three hours of reperfusion in the group of dogs treated with IB-MECA before occlusion. There were also no significant differences in blood pH, PO 2 , or PCO 2 within and between groups at any of the times studied (data not shown). 
Discussion
Adenosinergic therapy is one of the most promising pharmacological treatments for acute ischemia/reperfusion injury (28, 46). Clinically, adenosine has been shown to be effective when used in cardioplegic solutions (30) , when co-administered with thrombolytic agents (28), or when administered prior to coronary angioplasty (23) . The clinical usefulness of adenosine, however, is limited by its hemodynamic, respiratory, and CNS side effects in addition to its low potency and short half-life. Many of these problems could potentially be avoided by administering synthetic adenosine receptor ligands that are more selective for the individual adenosine receptor subtypes. In experimental animal models, agonists with high affinity for the A 2A AR including CGS 21680 (20) and AMP 579 (29, 38) have been shown to be effective at reducing infarct size when administered during reperfusion by reducing neutrophil-mediated injury and inflammation (8, 32, 48) . A 1 AR agonists are highly cardioprotective when administered prior to and during ischemia by producing favorable metabolic effects resulting in preservation of high-energy phosphates (46) .
We have recently focused on testing the efficacy of A 3 AR agonists in experimental models of ischemia/reperfusion injury (5, 21, 22, 41) . The A 3 AR is the most recently identified subtype of adenosine receptor that is coupled to G i/o inhibitory proteins similar to the A 1 AR (24). Using a chronically instrumented conscious rabbit model, we have observed that pre-treatment with IB-MECA (100 µg/kg) produced a significant protective effect against both reversible (myocardial "stunning") and irreversible injury (infarction) (5, 21) . In these studies, IB-MECA was effective when administered intravenously at a dose that had no effect on heart rate or systemic blood pressure (5, 21) . The protective effects of IB-MECA were blocked by the non-specific adenosine receptor antagonist 8- The results of the present investigation using a dog model of ischemia/reperfusion injury extend these previous observations. Similar to our previous studies in the rabbit, we found that pre-treatment with IB-MECA effectively reduced infarct size from ~25% of the AAR in control dogs to ~13% in dogs pre-treated with 100 µg/kg of IB-MECA ( Figure   3 ), a dose also found to be hemodynamically inactive in the dog (Figure 2 ). The novel aspect of the present study using the dog model is that we were able to provide more detailed assessment of IB-MECA on hemodynamics and coronary artery blood flow. Similar analyses have not been possible in previous studies conducted in rodents. At a dose of 100 µg/kg, we found that IB-MECA did not influence blood pressure, LV pressure, LV dP/dt, or the rate-pressure product (Table 1 and Figure 2 ). In addition, IB-MECA had no effect on coronary blood flow (Table 2 and Figure 2) . A lack of effect of IB-MECA on hemodynamic parameters was apparent during the ischemia/reperfusion studies as well as in preliminary studies in which the effects of IB-MECA were observed for 30 minutes in control barbital-anesthetized dogs. The lack of an effect of IB-MECA on coronary blood flow in these studies is an important observation since it rules against the possibility that it may cause coronary "steal", a complication that has been demonstrated to occur with dipyridamole (47) . In addition, the lack of hemodynamic effects suggests that IB-MECA was administered at a dose that did not influence other adenosine receptor subtypes in the heart or vasculature. By comparison, an equivalent dose of the A 1 AR agonist CCPA reduced heart rate, reduced systemic blood pressure, and increased coronary blood flow (Figure 2) . Overall, these results clearly suggest that the protective effects of IB-MECA are not dependent on changes in the oxygen supplydemand balance. Rather, they suggest that it acts via a direct cardioprotective mechanism. Previous studies using isolated hearts and isolated cardiomyocytes (9, 18, 19, 26, 33, 39, 40, 42-44) have suggested that A 3 ARs are expressed in the myocardium and that they couple to cardioprotective signaling mechanisms similar to those coupled to the A 1 AR, presumably the ATP-sensitive potassium channel. We predict that pretreatment with IB-MECA provided protection in our dog model by a comparable mechanism. This theory is supported by the observation that the reduction in infarct size provided by pre-treating with IB-MECA was blocked completely by glibenclamide.
One interesting aspect of the present investigation is that subendocardial blood flow was increased after three hours of reperfusion in the ischemic-reperfused myocardium in control animals ( Table 2 ). These data indicate that hyperemia developed in the subendocardial region, which we believe is related to the short period of ischemia utilized in our protocol. Importantly, the distribution of blood flow across the myocardium in the ischemic-reperfused region was identical in the two groups of dogs treated with IB-MECA, indicating further that IB-MECA had no effect on blood flow at the dose utilized in our investigation.
The second novel aspect of this work is that we found that IB-MECA was effective when administered at the time of reperfusion. In fact, we found that IB-MECA produced an equivalent reduction in infarct size whether it was administered 10 minutes before H-01001-2002-R2 13 the onset of ischemia or whether it was administered 5 minutes before the release of the occlusion. These results suggest that, in addition to exerting favorable effects during ischemia, IB-MECA produced beneficial actions that attenuated reperfusion injury. We predict that there are two potential mechanisms by which IB-MECA may have reduced reperfusion injury. The first is via an anti-inflammatory mechanism.
Jordan and colleagues (20) however, is by inhibiting apoptosis, since the A 3 AR is known to be capable of coupling to two well known cell survival signaling pathways including the phosphatidylinositol-3' (PI-3) kinase/akt kinase pathway (14, 37) and the Ras/Raf-1/MEK/Erk 1/2 pathway (37).
This potential mechanism is supported by the results of Maddock and colleagues, (27) who reported that Cl-IB-MECA reduced apoptosis of isolated rat cardiac myocytes subjected to simulated ischemia when administered during re-oxygenation. IB-MECA was originally shown to be ~50-fold selective for rat A 3 ARs versus rat A 1 and A 2A ARs (13) . Using canine adenosine receptors expressed in HEK 293 cells, we have also found in the present investigation that IB-MECA is ~50-fold more potent at binding to the canine A 3 AR versus the canine A 1 AR (Figure 1 ). These binding data coupled with the observation that IB-MECA was hemodynamically inactive in our in vivo studies suggest that the A 3 AR was the primary site of IB-MECA to reduce infarct size. It should be noted, however, that Linden's group (31) has recently provided evidence that 
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reported to cause a short-lived hypotension without any change in heart rate in rats and mice (11, 17, 45 28 Figure 3 
